even in the era of highly active antiretroviral therapy (HAART). In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of у5 kg who were receiving HAART. The mean weight was 66 kg, and the mean body mass index was 21. Mean weight gain in the megestrol acetate and the oxandrolone arms were 2.8 kg (4.6% of the baseline value) and 2.5 kg (3.9% of the baseline value), respectively ( ). Lean body mass accounted for 39% of weight gain in the megestrol acetate arm and P p .80 56% in the oxandrolone arm ( ). Seven patients in the megestrol acetate arm and 5 patients in the P p .38 oxandrolone arm reported minor adverse events ( ). In conclusion, megestrol acetate therapy and P p .74 oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART.
Weight loss is known to impact survival among patients infected with human immunodeficiency virus (HIV)
even in the era of highly active antiretroviral therapy (HAART). In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of у5 kg who were receiving HAART. The mean weight was 66 kg, and the mean body mass index was 21. Mean weight gain in the megestrol acetate and the oxandrolone arms were 2.8 kg (4.6% of the baseline value) and 2.5 kg (3.9% of the baseline value), respectively ( ). Lean body mass accounted for 39% of weight gain in the megestrol acetate arm and P p .80 56% in the oxandrolone arm ( ). Seven patients in the megestrol acetate arm and 5 patients in the P p .38 oxandrolone arm reported minor adverse events ( ). In conclusion, megestrol acetate therapy and P p .74 oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART.
Progressive weight loss in patients infected with HIV results in grave physiological and immunological consequences, including death [1] . In the pre-HAART era, HIV wasting syndrome was a common AIDS-defining illness (ADI) and occurred as the sentinel ADI in ∼18% of patients with AIDS [2] . Although HAART significantly reduces morbidity and prolongs life, even in the era of HAART, HIV-related weight loss (HRWL) re-mains a common complication [3] and a risk to the patient [4] .
The importance of treating HRWL is clear [1] , and reversal of weight loss is intended to reduce the risk of morbidity and mortality. Current approaches to treating HRWL include nutrition counseling and support, exercise therapy, and pharmacotherapy with appetite stimulants, anabolic steroids, and recombinant growth hormone [5] [6] [7] [8] [9] [10] . The efficacy of therapy with megestrol acetate (an appetite stimulant) and that of therapy with oxandrolone (an orally administered anabolic steroid) have each been tested and proven against placebo and other controls [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . On the basis of their respective modes of action, oxandrolone therapy would be expected to result in a greater increase in lean body mass (LBM) than therapy with megestrol acetate [7, 11, 22] . Whether this difference is apparent after a 2-month regime has also not been established. However, to the best of our knowledge, a comparison of the effects on HRWL of therapy with these 2 agents (particularly when received concurrently with HAART) has not previously been published.
The aim of this study was to compare the effects of megestrol acetate therapy with those of oxandrolone therapy (each administered for 2 months) on body weight and composition indices among a cohort of patients with documented weight loss of у5% during HAART. In addition, we compared the weight-gain medications in terms of patient tolerance and adverse event profile.
PATIENTS AND METHODS
Study design. Our study was designed as a randomized clinical trial comparing the effects of megestrol acetate therapy with those of oxandrolone therapy on body weight and composition over a 2-month period. Study participants were patients with HIV infection who were attending 1 of 2 community health centers located in the eastern part of Massachusetts or who were attending an infectious diseases clinic at an urban medical center in Boston. To participate in the study, patients had to be HIV positive and be receiving stable HAART. HAART was defined as any of the following regimens: 2 protease inhibitors (PIs), 1 PI and 2 nucleotide reverse-transcriptase inhibitors (NRTIs), or 1 nonnucleotide reverse-transcriptase inhibitor and 2 NRTIs. Patients were recruited for study participation after they had unintentionally lost у5% of their body weight during regular HIV clinic follow-up in the preceding 6 months. Exclusion criteria included the presence of any of the following: acute opportunistic infections, pregnancy, liver disease, kidney disease, thyroid disease, malignancies other than Kaposi sarcoma, or weight disorders. Patients who had been hypogonadal were permitted to continue to receive testosterone replacement therapy. Efforts were made to recruit women and minorities. At the time of enrollment, patient characteristics and clinical data were collected using a standardized questionnaire, and blood samples for laboratory examination were obtained. The institutional review boards of Tufts-New England Medical Center, of Beth Israel Deaconess Medical Center, and of the community health centers approved the protocol and procedures of this study.
Using computer-generated random numbers, participants were randomly assigned to 1 of 2 treatment arms to receive 2 months of therapy with either megestrol acetate (800 mg q.d.) or oxandrolone (10 mg b.i.d.). Patients were seen at enrollment and were followed up monthly. Complete data were collected at baseline and at 2 months after initiation of therapy. However, each monthly visit was used for dietary advice, prescription refills, and evaluation of adverse events.
Measurements. Body weight and height were obtained on a calibrated scale (Detecto) to the nearest 0.1 kg and 0.1 cm, respectively. All measurements were recorded by the same trained observer, with patients dressed in a hospital gown and not wearing shoes. Body mass index (BMI) was derived by dividing body weight by height squared (kg/m 2 ). Adherence to trial drug therapy was estimated by pill counts during study visits.
Midarm circumference, triceps skin-fold thickness, and subscapular skin-fold thickness were measured by a single observer to minimize variation. Standard tape measure and skin calipers were used for the circumference and skin-fold thickness measurements, respectively. All measurements were recorded to the nearest 0.1 cm. LBM and fat were estimated from these measures with use of the equation of Durnin and Womersley [23] .
Bioelectric impedance analysis was performed by a qualified nutritionist with use of a Quantum hand-held analyzer (RJL Systems) to measure resistance and reactance. Proportions of LBM and fat were derived using the equation of Lukaski [24] . In addition, body cell mass was estimated. The 12-item SF12 quality-of-life (SF12 QOL) tool [25] was used to collect data and evaluate health-related quality of life (HRQL) on a 0-100 scale in 2 domains: physical and mental. HRQL data were collected at baseline.
Nutrition counseling was initially provided before randomization and then at each monthly visit by a trained nutritionist. The nutrition counseling aims were designed to promote increased caloric intake to surpass daily energy requirements by 500 kcal per day, with suggested daily caloric intake of 40-50 kcal per kg of current body weight. Increased protein intake was suggested, with suggested daily protein intake of 1.6-1.8 g per kg of current body weight or double the daily requirements for anabolism. Through use of educational materials and careful assessment of their dietary patterns, participants were instructed on how to obtain the suggested energy and protein goals. Dietary counseling sessions were ∼30-60 min for each study visit, and continuous reinforcement of nutrient goals was emphasized throughout the study period.
Participants were asked to keep detailed dietary records of types and quantities of food consumed for the 3 days preceding each study visit. Participants were instructed on how to complete dietary food records with an emphasis on specifically and accurately recording all food and drink consumed. A 24-h recall was obtained for any participant with a missing food record. Daily dietary intake was estimated from these diary entries. Food items were converted to corresponding nutrient value using the Nutrition Data System for Research Software, version 4.02 (University of Minnesota).
HIV RNA levels were determined using the Roche Amplicor Monitor RT-PCR assay (Roche Molecular Systems) with a lower detection limit of 400 copies/mL (2.6 log 10 copies/mL). HIV loads were expressed as a log base-10 transformation (log 10 ). CD4 cells were counted using a fluorescent monoclonal antibody labeled cell sorter and expressed as cells per cubic mil- limeter. In addition, serum levels of albumin and cholesterol were obtained.
Adverse events were assessed monthly through self-reporting and evaluation of laboratory results. A patient with elevated transaminase levels was considered to have experienced an adverse event if 11 enzyme level reached у3 times the normal limit.
Statistical analyses. All analyses were performed on Statistical Analysis System (SAS Institute) software, version 8.02 SE (SAS). Patients with missing data were included in analyses of other variables if data for those variables were available.
This study was adequately powered to detect a difference of 2 kg in the increase in body weight (e.g., 2.0 kg vs. 4.0 kg or 2.5 kg vs. 4.5 kg) using 2-sided tests with power of 80% and a significance level of .05 between the 2 groups. Using pilot data, we estimated the sample size using a projected SD for the differences of 3 kg.
To compare the baseline demographic and clinical characteristics of the 2 arms, the Student's t test and the Wilcoxon rank sum test were used to formally test normally and nonnormally distributed continuous variables, respectively. The x 2 test and Fischer's exact test were used to test significance for all categorical variables. Ninety-five percent confidence intervals are given, and all P values are derived from 2-sided tests. P values р.05 were considered statistically significant.
Changes in the body weight and composition indices observed during this interval were calculated and compared between the 2 treatment arms using a paired sample Student's t test for normally distributed variables and the Wilcoxon rank sum test for the nonnormal variables.
RESULTS
Forty participants, enrolled between November 1997 and April 2000, were randomized to receive either megestrol acetate therapy or oxandrolone therapy. One participant in the oxandrolone group later declined to participate. Of the 39 patients who started treatment, 33 were seen at the 2-month visit. Figure 1 shows the participant count flowchart. There were no demonstrable statistically significant differences in characteristics at baseline between those who were later lost to follow-up and those observed to the end of the 2-month period.
Baseline characteristics. The average age of the study sample participants was 40 years. Seventy-five percent of the participants were male, 38% were of Hispanic origin, and 13% were African American. Thirty-eight percent of participants cited injection drug use (IDU) as the primary risk factor associated with contracting HIV infection, and 43% cited homosexual contact as their primary risk factor associated with contracting HIV infection; a previous history of an ADI was reported by 84.5% of participants [26] . For participants, the mean weight, BMI, and percentage of body fat were 62.5 kg, 21, and 16.5%, respectively. The average total energy intake and total energy intake per kg of body weight were 2500 kcal per day and 41.2 kcal/kg per day, respectively. The average SF12 QOL scores (0-100 scale) were 41.3 and 43.7 for the physical and mental components of HRQL, respectively. The median CD4 cell count and median virus load were 320 cells/mm 3 and 2.7 log 10 copies/mL, respectively. There were no demonstrable significant differences in the baseline characteristics between the 2 treatment arms. Demographic and clinical characteristics at baseline for participants in each treatment arm are shown in table 1. The mean BMI at enrollment was 20.8 for the megestrol acetate arm and 21.3 for the oxandrolone arm.
Randomized controlled trial analysis. All body mass and composition indices were increased in both arms of the study after 2 months of treatment. The increases within each group in total body weight, BMI, and fat were statistically significant for both groups. In addition, the increase in body cell mass within the megestrol group and the increase in LBM within each group were also statistically significant. There were no significant differences between the 2 treatment arms. The average increase in weight was 2.8 kg (4.6% of weight at baseline) in the megestrol acetate arm and 2.5 kg (3.9%) in the oxandrolone arm ( ), and the average BMI increased from P p .8 20.8 to 22.1 in the megestrol acetate arm and 21.3 to 22.2 in the oxandrolone arm ( ). Weight gain was noted in 72% P p .66 of those in the megestrol acetate arm and 80% of those in the oxandrolone arm ( ). In the megestrol acetate arm, gains P p .69 in fat and in LBM, as determined by bioelectric impedance analysis, were 1.7 kg and 1.1 kg, respectively; in the oxandrolone arm, they were 1.1 kg and 1.4 kg, respectively. LBM accounted for 39% of weight gain in the megestrol acetate arm and 56% of weight gain in the oxandrolone arm; however, this difference between the 2 arms was not statistically significant ( ). P p .38 These and other specific differences between the 2 treatment arms are shown in table 2. There were no significant changes in CD4 cell count or virus load during the course of the study.
There were 7 participants in the megestrol acetate arm and 5 in the oxandrolone arm who reported adverse events (P p ). The profiles of reported adverse events were different in .74 the 2 treatment arms. The main adverse events reported in the megestrol acetate arm were nausea and being "bloated and swollen"; those reported in the oxandrolone arm were elevated transaminase levels. These reported adverse events are shown in table 3.
DISCUSSION
This randomized-trial analysis showed that both megestrol acetate therapy and oxandrolone therapy significantly increased body weight, BMI, fat, LBM, and body cell mass in a population with HRWL. After 2 months of therapy, the differences between the effects of the 2 agents were not significant, even after adjusting for sex and testosterone replacement therapy. In addition, both agents were safe and well tolerated. Patients who had lost у 5% of their weight during a 6-month period and who received megestrol acetate therapy for 2 months regained an average of 4.6% of their body weight; those who received oxandrolone therapy regained an average of 3.7%. Randomized controlled trials comparing the effects of megestrol acetate therapy and oxandrolone therapy on body mass and composition in patients with HRWL have not previously been published in peer-reviewed literature. However, similar but larger trials may be either in progress or in analysis [20] . There are studies that have compared megestrol acetate therapy with therapy involving other injectable anabolic steroids, including nandrolone and testosterone [13, 14] . In a study [13] comparing patients who received 3 months of megestrol acetate therapy with patients who received 3 months of nandrolone therapy, patients in the megestrol acetate arm experienced a mean gain in fat of 7.54 kg and a mean gain in fat-free mass of 2.76 kg; the nandrolone group experienced a significant mean increase in fat of 3.2 kg and a mean increase in fat-free mass of 3.54 kg.
The respective effects on HRWL of megestrol acetate therapy and oxandrolone therapy as compared with the effects of placebo have been shown previously and are similar to those observed here [7, 18, 27, 28] . Although we did not find significant differences in body weight change between the 2 arms, we observed interesting nonsignificant trends with regard to increases in fat and LBM. As expected (given the respective modes of action of each agent), there was a greater increase in LBM in the oxandrolone group than in the megestrol acetate group, and the reverse was seen with regard to increases in fat. Other possible explanations for the weight gain include a possibly associated reduction in virus load or an increase in CD4 cell count. We examined these parameters and found that both had not changed significantly during the course of the study. The use of testosterone among some male patients may be construed as a potential source of interference with the outcomes. However, all of these patients were hypogonal and were receiving replacement therapy to achieve eugonadal status.
Contrary to expectations, we observed a smaller increase in food and energy intake in the megestrol acetate group. Although this difference was nonsignificant, one is compelled to ask whether this difference influenced the outcome of the study. When we examined these data more closely, we found that 4 participants in the megestrol acetate group had experienced a large decrease in caloric intake (of 1500 kcal/day) during the course of the study. Of these 4 patients with reported reductions in energy intake, 1 had received one-half of the recommended dosage of megestrol acetate and had gained 4 kg during the 2 months of therapy; 1 had reported vomiting, and megestrol acetate was consequently withdrawn for 2 weeks during the study period; 1 later had hepatocellular carcinoma diagnosed; and 1 had received one-half of the recommended dose and had remained the same weight. Excluding these 4 participants from the study would result in a mean energy intake of 640 kcal per day (instead of 187 kcal per day) for the megestrol acetate arm. However, because of the relatively small total number of participants in the study, we included data for these participants in all of our analyses. The nonsignificant difference observed in energy intake between the 2 treatment arms suggests that nutritional counseling may have played a role in reducing the difference in weight gain between the megestrol acetate and oxandrolone arms. However, because our study population consisted of patients who had lost у5% of their body weight despite receiving continued dietary advice, it was in the interest of the patients to test more-aggressive approaches. There was no significant difference observed in the number of participants who reported adverse events in the 2 arms of the study. However, the profiles of the reported adverse events were dissimilar. In addition, the elevated transaminase levels observed in the patients receiving oxandrolone therapy reverted to normal levels when therapy was discontinued or when the dose was reduced. Although this study was not designed to assess the details of adverse events, this observation may potentially benefit clinical practice when making a choice between these agents.
The strengths of this study include that the sample population was reflective of the HIV epidemic in the United States, that all subjects had experienced recent weight loss (documented during recent clinic visits), and that we studied a population that was receiving HAART. In addition, the study was adequately powerful to detect a reasonably small difference in the increase in body weight. Studies published after the initiation of this study support the parameter estimates we chose to use in our sample size calculations [13, 28] . The limitations of this study include the rate of patients who dropped out of the study or were lost to follow-up and the lack of blinding in the trial design. Blinding would have been difficult, particularly because the megestrol acetate agents are formulated as a suspension and the oxandrolone agents are formulated as tablets. However, the randomization was successful, and the baseline characteristics of patients who dropped out of the study or were lost to follow-up and those of patients who completed the study were not dissimilar. The use of placebo is debatable with regard to ethical standards of providing adequate care to patients with a known increased risk of mortality and morbidity. When interpreting these results, one must bear in mind the difficulties involved in recruitment and retention of participants for these types of studies, especially given the diverse community from which this study population was recruited. The complex nature of HIV infection, its complications, and its treatment contribute significantly towards a smaller yield of participants when attempting to recruit and retain patients with known weight loss. Furthermore, reporting these findings will be informative regarding trends of the possible effects of the agents, as well as regarding the reality of undertaking studies in this field. Thus, we believe these data are valuable to those planning future studies involving HIV-infected communities in the era of HAART.
In conclusion, during HAART, if patients experience significant weight loss that may pose a threat, treatment with 2 months of megestrol acetate therapy or oxandrolone therapy, administered in conjunction with nutritional counseling, can benefit patients by providing a modest gain in body weight and BMI. Under these circumstances, the 2 agents are similar in their respective effects on body weight, as well as in their specific effects on LBM and fat. Although adverse event profiles are different for the 2 agents, both are safe and well tolerated. Individually, these agents are successful in increasing body weight and BMI in patients with HRWL, but they do not succeed in returning weight or BMI to within normal ranges.
